دورية أكاديمية
أعرض في EDS

Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.

التفاصيل البيبلوغرافية
العنوان: Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
المؤلفون: Powers GL; Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin., Hammer KD; Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin., Domenech M; Department of Biomedical Engineering and Wisconsin Institute for Medical Research, University of Wisconsin-Madison, Madison, Wisconsin. Department of Chemical Engineering, University of Puerto Rico, Mayaguez, Puerto Rico., Frantskevich K; Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin., Malinowski RL; Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin., Bushman W; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin., Beebe DJ; Department of Biomedical Engineering and Wisconsin Institute for Medical Research, University of Wisconsin-Madison, Madison, Wisconsin., Marker PC; Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin. marker@wisc.edu.
المصدر: Molecular cancer research : MCR [Mol Cancer Res] 2015 Jan; Vol. 13 (1), pp. 149-60. Date of Electronic Publication: 2014 Aug 22.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research, c2002-
مواضيع طبية MeSH: Cell Proliferation/*drug effects , Cyclic Nucleotide Phosphodiesterases, Type 4/*genetics , Prostatic Neoplasms/*drug therapy , Prostatic Neoplasms/*genetics, Animals ; Cyclohexanecarboxylic Acids/administration & dosage ; Hedgehog Proteins/biosynthesis ; Humans ; Male ; Mice ; Mitogen-Activated Protein Kinase Kinases/biosynthesis ; Naphthyridines/administration & dosage ; Nitriles/administration & dosage ; Oxadiazoles/administration & dosage ; Phosphodiesterase 4 Inhibitors/administration & dosage ; Receptors, Androgen/biosynthesis ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays
مستخلص: Unlabelled: Phosphodiesterase 4D (PDE4D) has recently been implicated as a proliferation-promoting factor in prostate cancer and is overexpressed in human prostate carcinoma. However, the effects of PDE4D inhibition using pharmacologic inhibitors have not been examined in prostate cancer. These studies examined the effects of selective PDE4D inhibitors, NVP-ABE171 and cilomilast, as anti-prostate cancer therapies in both in vitro and in vivo models. The effects of PDE4D inhibitors on pathways that are critical in prostate cancer and/or downstream of cyclic AMP (cAMP) were examined. Both NVP-ABE171 and cilomilast decreased cell growth. In vitro, PDE4D inhibitors lead to decreased signaling of the sonic hedgehog (SHH), androgen receptor (AR), and MAPK pathways, but growth inhibition was best correlated to the SHH pathway. PDE4D inhibition also reduced proliferation of epithelial cells induced by paracrine signaling from cocultured stromal cells that had activated hedgehog signaling. In addition, PDE4D inhibitors decreased the weight of the prostate in wild-type mice. Prostate cancer xenografts grown in nude mice that were treated with cilomilast or NVP-ABE171 had decreased wet weight and increased apoptosis compared with vehicle-treated controls. These studies suggest the pharmacologic inhibition of PDE4D using small-molecule inhibitors is an effective option for prostate cancer therapy.
Implications: PDE4D inhibitors decrease the growth of prostate cancer cells in vivo and in vitro, and PDE4D inhibition has therapeutic potential in prostate cancer.
(©2014 American Association for Cancer Research.)
References: Br J Pharmacol. 2011 May;163(1):53-67. (PMID: 21232047)
Mol Cancer. 2004 Oct 13;3:29. (PMID: 15482598)
Cell. 2000 Feb 18;100(4):423-34. (PMID: 10693759)
Integr Biol (Camb). 2012 Feb;4(2):142-52. (PMID: 22234342)
Biochem J. 2000 Apr 15;347(Pt 2):571-8. (PMID: 10749688)
J Pathol. 2008 Dec;216(4):460-70. (PMID: 18825689)
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20611-6. (PMID: 24218555)
Eur Urol. 2006 Apr;49(4):740-5. (PMID: 16460876)
Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2). (PMID: 10881018)
Dev Dyn. 2012 Dec;241(12):2005-13. (PMID: 23074159)
Biochem Pharmacol. 2010 Feb 1;79(3):321-9. (PMID: 19737543)
Semin Cell Dev Biol. 2012 Apr;23(2):181-90. (PMID: 21930230)
J Biol Chem. 2007 Dec 28;282(52):37370-7. (PMID: 17895245)
Genes Dev. 1996 Mar 15;10(6):647-58. (PMID: 8598293)
Biol Reprod. 1986 Jun;34(5):973-83. (PMID: 3730489)
Cell Signal. 2008 Jan;20(1):139-53. (PMID: 18006274)
J Urol. 2007 Mar;177(3):1179-85. (PMID: 17296441)
N Engl J Med. 2012 Jun 7;366(23):2171-9. (PMID: 22670903)
Br J Clin Pharmacol. 2006 Aug;62(2):138-52. (PMID: 16842388)
J Biomed Sci. 2011 Jan 18;18:6. (PMID: 21241512)
Stem Cells. 2010 Feb;28(2):344-56. (PMID: 20020426)
Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7. (PMID: 16402111)
Pharmacol Toxicol. 1994 Aug;75(2):108-12. (PMID: 7971738)
J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. (PMID: 11907180)
Prostate. 2006 Sep 15;66(13):1347-58. (PMID: 16752376)
Prostate. 2011 Dec;71(16):1711-22. (PMID: 21520153)
Endocrinology. 2004 Aug;145(8):3961-70. (PMID: 15132968)
J Biol Chem. 2003 Feb 21;278(8):5493-6. (PMID: 12493749)
Clin Cancer Res. 2005 Feb 1;11(3):971-81. (PMID: 15709162)
Dev Biol. 1999 May 1;209(1):28-39. (PMID: 10208740)
J Pathol. 2012 May;227(1):29-41. (PMID: 22362584)
Cell. 2013 Apr 25;153(3):666-77. (PMID: 23622249)
Cancer Res. 2007 Jul 1;67(13):6083-91. (PMID: 17616663)
Cochrane Database Syst Rev. 2011 May 11;(5):CD002309. (PMID: 21563134)
Urol Oncol. 2014 Jan;32(1):25.e1-12. (PMID: 23410945)
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. (PMID: 16514137)
Mol Biol Cell. 2009 Nov;20(22):4751-65. (PMID: 19759179)
J Biol Chem. 1999 Mar 19;274(12):7777-83. (PMID: 10075669)
Histopathology. 2011 Jun;58(7):1037-47. (PMID: 21707705)
Oncogene. 2005 Nov 21;24(52):7729-45. (PMID: 16299533)
Mol Pharmacol. 2007 Jul;72(1):73-85. (PMID: 17430995)
Cancer Res. 2009 May 15;69(10):4388-97. (PMID: 19401450)
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6109-14. (PMID: 23536305)
Oncogene. 2013 Feb 28;32(9):1121-34. (PMID: 22525277)
Exp Dermatol. 2012 Nov;21(11):847-52. (PMID: 23163650)
In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24. (PMID: 7535634)
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3556-60. (PMID: 1373503)
Oncogene. 2009 Dec 17;28(50):4480-90. (PMID: 19784071)
Integr Biol (Camb). 2009 Mar;1(3):267-74. (PMID: 20011455)
Prog Nucleic Acid Res Mol Biol. 2001;69:249-315. (PMID: 11550796)
معلومات مُعتمدة: R01 CA140217 United States CA NCI NIH HHS; R01 DK091193 United States DK NIDDK NIH HHS; F32 CA141798 United States CA NCI NIH HHS; CA140217 United States CA NCI NIH HHS; U54 DK104310 United States DK NIDDK NIH HHS; K01 CA188167 United States CA NCI NIH HHS; T32 CA157322 United States CA NCI NIH HHS; DK091193 United States DK NIDDK NIH HHS; CA141798 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Cyclohexanecarboxylic Acids)
0 (Hedgehog Proteins)
0 (NVP ABE171)
0 (Naphthyridines)
0 (Nitriles)
0 (Oxadiazoles)
0 (Phosphodiesterase 4 Inhibitors)
0 (Receptors, Androgen)
0 (SHH protein, human)
8ATB1C1R6X (Cilomilast)
EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4)
تواريخ الأحداث: Date Created: 20140824 Date Completed: 20150916 Latest Revision: 20211021
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4312503
DOI: 10.1158/1541-7786.MCR-14-0110
PMID: 25149359
قاعدة البيانات: MEDLINE
الوصف
تدمد:1557-3125
DOI:10.1158/1541-7786.MCR-14-0110